Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Case Report Volume 5 Issue 10

New Onset Encephalopathy Associated with Ivermectin Use

Samridh Gupta1, Jin Tao2, Vibhav Bansal3*, Sarah Linder1, Vijayta Geeta Bansal-Kapuria1, Drew Rust1, Paul Jacob Pecorin1 and Katherine Firch1

1University of Chicago College of Medicine, Rockford, IL, USA
2Internal Medicine, MercyHealth, Rockford, IL, USA
3Deparment of Neurology, Mercy Health Rockford, IL- USA

*Corresponding Author: Vibhav Bansal, Deparment of Neurology, Mercy Health Rockford, IL- USA.

Received: August 06,2022; Published: September 20, 2022


Ivermectin, an anthelmintic medication used to treat parasitic infections, has gained recent attention for

possible treatment of COVID-19. COVID-19 is an infectious disease caused by the SARS-Co-V-2 virus.

Ivermectin has been associated with severe adverse side effects including encephalopathy. Here, we report a

case of a 76-year-old male with no significant past medical history presented with new onset encephalopathy following three days of self-medicated ivermectin use in treating COVIC -19 pneumonia. As a result of his altered mentation, he fell down 12-step staircase and experienced traumatic head injury with loss of consciousness. On admission, his head CT without contrast showed traumatic intracerebral hemorrhage bilaterally in the frontal and temporal lobes, subarachnoid hemorrhage, and nondisplaced left occipital and mastoid temporal fracture. No intervention was recommended at that time by neurosurgery. Patient’s Covid-19 pneumonia was treated with 5-day course of remdesivir and 10-day course of dexamethasone along with use of supplemental oxygen. His respiratory status improved overtime, but his neurological status continued to decline. Unfortunately, patient passed away after five weeks of hospital stay. Encephalopathy is a rare side effect of ivermectin. Our case highlights the dangers of self-medication in treating COVID -19 pneumonia. We would like to encourage health care providers to educate patients about the potential adverse effects of off-label ivermectin use.

Keywords: Ivermectin; Encephalopathy; Confusion; Behavior Changes; Covid-19; Intracerebral Hemorrhage; Subarachnoid Hemorrhage; Ataxia


  1. Caly Leon., et al. “The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-COV-2 in Vitro”. Antiviral Research 178 (2020): 104787.
  2. Campillo Jérémy T., et al. “Serious Adverse Reactions Associated with Ivermectin: A Systematic Pharmacovigilance Study in Sub-Saharan Africa and in the Rest of the World”. PLOS Neglected Tropical Diseases4 (2021).
  3. Chandler Rebecca E. “Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?” The American Journal of Tropical Medicine and Hygiene2 (2018): 382-388.
  4. Gams, Daniel Massi, et al. “Post-Ivermectin Encephalopathy in Senegal: A Case Report”. Pan African Medical Journal 27 (2017).
  5. “Ivermectin”. National Institutes of Health, U.S. Department of Health and Human Services (2022).
  6. Morales Juan., et al. “Acute Encephalopathy after Self Medication with Ivermectin in a Patient with COVID-19”. Chest4 (2021).
  7. Nzolo, Didier, et al. “Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System”. Drugs - Real World Outcomes3 (2017): 151-158.
  8. “Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19”. Centers for Disease Control and Prevention (2021).
  9. “States Ranked by Percentage of Population Fully Vaccinated”. Becker's Hospital Review.
  10. Temple Courtney., et al. “Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19”. New England Journal of Medicine23 (2021): 2197-2198.
  11. Worobey Michael. “Dissecting the Early COVID-19 Cases in Wuhan”. Science6572 (2021): 1202-1204.
  12. Twum-Danso Nana AY. “Loa Loa Encephalopathy Temporally Related to Ivermectin Administration Reported from Onchocerciasis Mass Treatment Programs from 1989 to 2001: Implications for the Future - Filaria Journal”. BioMed Central, BioMed Central (2003).


Citation: Vibhav Bansal.,et al. “A Case of Localized Amyloid Angiopathy Following Aneurysmal Subarachnoid Hemorrhage - Strong Evidence of Dysfunction of the Glymphatic System”. Acta Scientific Neurology 5.10 (2022): 30-32.


Copyright: © 2022 Vibhav Bansal.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US